Skip to Content

Unituxin

Active Substance: dinutuximab
Common Name: dinutuximab
ATC Code: L01XC
Marketing Authorisation Holder: United Therapeutics Europe Ltd
Active Substance: dinutuximab
Status: Withdrawn
Authorisation Date: 2015-08-14
Therapeutic Area: Neuroblastoma
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.

The marketing authorisation for Unituxin has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide